9 July 2010 / TODAY’S ZAMAN, İSTANBUL
Denmark’s leading pharmaceuticals manufacturer, Nycomed, has entered the Turkish market, with an annual turnover target of $25 million for this year, a company official announced on Thursday.
Speaking to reporters in İstanbul, Nycomed’s Executive Vice President for Commercial Operations Guido Oelkers said their company has concentrated their investment in developing markets like Turkey and that they have faith the country’s drug market will offer new investment opportunities. “The Turkish drug market has maintained a steady growth thanks to substantial infrastructure investments,” he said and added that the country is poised to become a prominent player in the global drug market. Oelkers noted that Nycomed expected to become one of the 20 leading drug firms in Turkey within the following four years. The company manager said they would seek opportunities in the market in a bid to realize this goal.
Nycomed Turkey General Manager Bedri Toker said they expected to achieve $25 million in turnover from operations in Turkey for 2010. The manager said they would employ 130 people in-country initially.
